Recent News

• 09.12.2025 - ProPhase Labs Stockholders Approve All Proposals at September 9, 2025 Special Meeting By More Than 75% In Favor
• 09.12.2025 - ProPhase Labs Stockholders Approve All Proposals at September 9, 2025 Special Meeting By More Than 75% In Favor
• 09.03.2025 - ProPhase Labs Inc. to Participate in Renmark’s Virtual Non-Deal Roadshow Series on Thursday, September 4, 2025
• 09.03.2025 - ProPhase Labs Inc. to Participate in Renmark’s Virtual Non-Deal Roadshow Series on Thursday, September 4, 2025
• 08.19.2025 - ProPhase Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of Shareholders
• 08.19.2025 - ProPhase Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of Shareholders
• 08.13.2025 - ProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025
• 08.13.2025 - ProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025
• 08.12.2025 - ProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk Assessment
• 08.12.2025 - ProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk Assessment

Recent Filings

• 09.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.28.2025 - 8-K Current report
• 08.19.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 08.19.2025 - 8-K Current report
• 08.19.2025 - EX-99.1 EX-99.1
• 08.15.2025 - DEF 14A Other definitive proxy statements
• 08.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.13.2025 - 8-K Current report
• 08.13.2025 - EX-99.1 EX-99.1